Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tsoutsos

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The British Journal of Dermatology|January 17, 2007
p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variantsI Stefanaki, A J Stratigos, G Dimisianos, et al.
Cancer Investigation|January 12, 2005
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology GroupHelen Gogas, D Bafaloukos, G Aravantinos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2005
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology GroupD Bafaloukos, D Tsoutsos, H Kalofonos, et al.
The British Journal of Dermatology|April 23, 2014
Demographic, behavioural and physician-related determinants of early melanoma detection in a low-incidence populationJ A Talaganis, K Biello, M Plaka, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The British Journal of Dermatology|January 17, 2007
p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variantsI Stefanaki, A J Stratigos, G Dimisianos, et al.
Cancer Investigation|January 12, 2005
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology GroupHelen Gogas, D Bafaloukos, G Aravantinos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2005
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology GroupD Bafaloukos, D Tsoutsos, H Kalofonos, et al.
The British Journal of Dermatology|April 23, 2014
Demographic, behavioural and physician-related determinants of early melanoma detection in a low-incidence populationJ A Talaganis, K Biello, M Plaka, et al.
Pageof 3